Clinical Trial Update: Saroglitazar Magnesium 4 mg for Nonalcoholic Fatty Liver Disease (NAFLD) in People Living With HIV in the US [Phase 2]

View source ↗

Summary

A Phase 2 study of saroglitazar magnesium for nonalcoholic fatty liver disease in people living with HIV was terminated in the US, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Nonalcoholic Fatty Liver Disease

Drugs mentioned

• Saroglitazar Magnesium (saroglitazar magnesium)

Snippet

Sponsor: Zydus Therapeutics Inc. | Conditions: Nonalcoholic Fatty Liver Disease | Phase 2 | Status: TERMINATED | Results posted: 2025-07-16